Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial

Clinical Breast Cancer

Volumn 11, Issue 2, 2011, Pages 82-92

  Robert, Nicholas J ^a   Saleh, Mansoor N ^b   Paul, Devchand ^c   Generali, Daniele ^d   Gressot, Laurent ^e   Copur, Mehmet S ^f   Brufsky, Adam M ^g   Minton, Susan E ^h   Giguere, Jeffrey K ⁱ   Smith II, John W ^j   Richards, Paul D ^k   Gernhardt, Diana ^l   Huang, Xin ^l   Liau, Katherine F ^l   Kern, Kenneth A ^l   Davis, John ^m  

^a Virginia Cancer Specialists   (United States)

^b Georgia Cancer Specialists   (United States)

^c Rocky Mountain Cancer Center   (United States)

^d Centro di Medicina Molecolare   (Italy)

^e Cancer Center   (United States)

^f Saint Francis Cancer Treatment Center   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ Cancer Centers of the Carolinas   (United States)

^j Northwest Cancer Specialists   (United States)

^k Blue Ridge Cancer Care   (United States)

^l PFIZER INC   (United States)

^m Kansas City Cancer Centers   (United States)

more..

Author keywords

Advanced breast cancer; Bevacizumab; Paclitaxel; Sunitinib malate; Tyrosine kinase inhibitor

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN; PACLITAXEL; SUNITINIB; TAXANE DERIVATIVE;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOCYTE; LEUKOPENIA; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRESCRIPTION; PROFESSIONAL STANDARD; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 80051713290     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.03.005     Document Type: Article

References (28)

1. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81.
2. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM Breast cancer. V. I.2010:2009.
4. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
5. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60.
6. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
7. Pasanisi P, Venturelli E, Morelli D, et al. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 2008;17:1719-22.
8. Paulsson J, Sjoblom T, Micke P, et al. Prognostic significance of stromal plateletderived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009;175:334-41.
9. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95. (Pubitemid 36554699)
10. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006;5:1280-9. (Pubitemid 43881321)
11. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
12. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-6. (Pubitemid 44536887)
13. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37. (Pubitemid 36109749)
14. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66. (Pubitemid 38019277)
15. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605. (Pubitemid 36857948)
16. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2:1011-21.
17. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-6.
18. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75.
19. Barrios CH, Hernandez-Barajas D, Brown MP et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Eur J Cancer 2009;7(2 Suppl):429 (Abstract P-7122).
20. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68.
21. Kozloff M, Chuang E, Starr A, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010;21:1436-41.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
23. Gradishar WJ, Kaklamani V, Prasad Sahoo T, et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). Cancer Res 2009;69(24 Suppl):(Abstract 44).
24. Baselga J, Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H, et al. A multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 2009;69(24 Suppl):(Abstract 45).
25. ® (paclitaxel) Injection [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2007. Available at http://www.bms.com/products/Pages/ prescribing.aspx. (accessed March12, 2011).
26. Sutent (sunitinib malate) capsules, oral [package insert]. New York, NY: Pfizer, 2010. Available at http://www.pfizer.com/products/rx/rx-product-sutent. jsp. (accessed March 12, 2011).
27. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7.
28. ™ myeloid growth factors. V. I.2010:2009.